MCID: SQM006
MIFTS: 57

Squamous Cell Carcinoma

Categories: Cancer diseases, Rare diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Squamous Cell Carcinoma

MalaCards integrated aliases for Squamous Cell Carcinoma:

Name: Squamous Cell Carcinoma 11 19 75 28 5 14 16 71
Carcinoma, Squamous Cell 19 75 43
Epidermoid Carcinoma 11 19 75
Squamous Cell Cancer 11 53 14
Squamous Cell Carcinoma - Category 71
Malignant Squamous Cell Neoplasm 71
Squamous Cell Carcinoma of Skin 71
Malignant Squamous Cell Tumor 11
Squamous Cell Epithelioma 11
Squamous Cell Skin Cancer 19
Neoplasms, Squamous Cell 43
Carcinoma Squamous Cell 53
Squamous Carcinoma 11

Classifications:



External Ids:

Disease Ontology 11 DOID:1749
NCIt 49 C2929
SNOMED-CT 68 154605007
UMLS 71 C0007137 C0553723 C0751688 more

Summaries for Squamous Cell Carcinoma

GARD: 19 Squamous cell carcinoma (SCC) is the second most common skin cancer. SCC most often affects individuals who are exposed to large amounts of sunlight. It is typically characterized by a red papule or plaque with a scaly or crusted surface; it may be suspected whenever a small, firm reddish-colored skin lesion, growth or bump appears on the skin, but it may also be a flat growth with a curly and crusted surface. Most often these growths are located on the face, ears, neck, hands and/or arms, but they may occur on the lips, mouth, tongue, genitalia or other area. The most common causes of SCC are radiation from the sun and arsenic exposure.

MalaCards based summary: Squamous Cell Carcinoma, also known as carcinoma, squamous cell, is related to squamous cell carcinoma, head and neck and esophageal cancer. An important gene associated with Squamous Cell Carcinoma is DDR2 (Discoidin Domain Receptor Tyrosine Kinase 2). The drugs Petrolatum and Mometasone furoate have been mentioned in the context of this disorder. Affiliated tissues include skin, lymph node and tongue.

Disease Ontology: 11 A carcinoma that derives from squamous epithelial cells.

Wikipedia: 75 Squamous-cell carcinomas (SCCs), also known as epidermoid carcinomas, comprise a number of different... more...

Related Diseases for Squamous Cell Carcinoma

Diseases related to Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2256)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma, head and neck 33.8 SPRY4-IT1 MIR205 HOTAIR H19 EPIST
2 esophageal cancer 33.6 UCA1 MIR205 MALAT1 HOTAIR H19 CDKN2B-AS1
3 esophagus squamous cell carcinoma 33.6 TUG1 TINCR MALAT1 HOTAIR EPIST CASC9
4 oral squamous cell carcinoma 33.4 UCA1 TUG1 NEAT1 MIR205 MALAT1 HOTAIR
5 laryngeal squamous cell carcinoma 33.3 NEAT1 MALAT1 HOTAIR H19 CDKN2B-AS1
6 nasopharyngeal carcinoma 32.7 NEAT1 MIR205 MALAT1 HOTAIR HNF1A-AS1 H19
7 lung squamous cell carcinoma 32.6 TUG1 DDR2 CCAT2
8 lung cancer susceptibility 3 32.2 TUG1 MIR205 MALAT1 HOTAIR HNF1A-AS1 H19
9 small cell cancer of the lung 32.0 TUG1 MALAT1 HOTAIR CCAT2
10 prostate cancer 31.9 UCA1 TUG1 SPRY4-IT1 NEAT1 MIR205 MALAT1
11 lung cancer 31.8 UCA1 TUSC7 TUG1 TINCR SPRY4-IT1 RIOX2
12 bladder cancer 31.8 ZEB1-AS1 UCA1 TUG1 TINCR SPRY4-IT1 MIR205
13 melanoma 31.8 UCA1 SPRY4-IT1 MIR205 MALAT1 HOTAIR H19
14 thyroid carcinoma 31.8 UCA1 NEAT1 MALAT1 HOTAIR H19 CDKN2B-AS1
15 cervical cancer 31.8 UCA1 TUG1 SPRY4-IT1 NEAT1 MIR205 MALAT1
16 thyroid cancer, nonmedullary, 1 31.7 NEAT1 MALAT1 HOTAIR H19
17 endometrial cancer 31.5 UCA1 TUSC7 TUG1 NEAT1 HOTAIR H19
18 gallbladder cancer 31.4 UCA1 TUG1 MALAT1 HOTAIR H19 CDKN2B-AS1
19 gastric adenocarcinoma 31.4 NEAT1 HOTAIR H19
20 gastric cardia adenocarcinoma 31.3 HOTAIR H19 EPIST
21 retinitis pigmentosa 11 31.2 UCA1 TUG1 NEAT1 HOTAIR CDKN2B-AS1 CCAT2
22 pancreatic cancer 31.1 UCA1 TUG1 SPRY4-IT1 NEAT1 MIR205 MALAT1
23 myeloma, multiple 31.1 UCA1 TUG1 MALAT1 HOTAIR H19
24 ovarian cancer 31.1 UCA1 TUG1 SPRY4-IT1 NEAT1 MIR205 MALAT1
25 bladder urothelial carcinoma 31.1 TUG1 MALAT1 HOTAIR
26 leukemia, acute myeloid 31.1 UCA1 TUSC7 TUG1 MALAT1 HOTAIR CDKN2B-AS1
27 cholangiocarcinoma 31.0 UCA1 TUG1 SPRY4-IT1 NEAT1 MALAT1 H19
28 renal cell carcinoma, nonpapillary 31.0 UCA1 TUG1 SPRY4-IT1 MALAT1 HOTAIR H19
29 gastrointestinal system cancer 30.9 MIR205 MALAT1 HOTAIR H19
30 pancreatic ductal adenocarcinoma 30.9 UCA1 TUSC7 MIR205 MALAT1 HOTAIR H19
31 congestive heart failure 30.6 TUSC7 HOTAIR CDKN2B-AS1
32 osteogenic sarcoma 30.6 ZEB1-AS1 UCA1 TUSC7 TUG1 NEAT1 MALAT1
33 ovarian epithelial cancer 30.6 MALAT1 HOTAIR H19 CCAT2
34 hepatocellular carcinoma 30.6 ZEB1-AS1 UCA1 TUSC7 TUG1 SPRY4-IT1 RIOX2
35 gastric cancer 30.6 ZEB1-AS1 UCA1 TUSC7 TUG1 TINCR SPRY4-IT1
36 pre-eclampsia 30.6 TUG1 SPRY4-IT1 MALAT1 HOTAIR H19
37 pituitary adenoma 30.3 MALAT1 HOTAIR H19 CCAT2
38 colorectal cancer 30.3 ZEB1-AS1 UCA1 TUSC7 TUG1 TINCR SPRY4-IT1
39 glioma 30.2 ZEB1-AS1 UCA1 SPRY4-IT1 NEAT1 MALAT1 HOTAIR
40 high grade glioma 30.1 TUSC7 TUG1 SPRY4-IT1 NEAT1 MALAT1 HOTAIR
41 retinitis pigmentosa 30.0 ZEB1-AS1 UCA1 TUG1 TINCR NEAT1 HOTAIR
42 osteoarthritis 29.8 HOTAIR H19 DDR2
43 skin squamous cell carcinoma 11.9
44 penis squamous cell carcinoma 11.8
45 cervical squamous cell carcinoma 11.8
46 tongue squamous cell carcinoma 11.8
47 palmoplantar hyperkeratosis with squamous cell carcinoma of skin and 46,xx sex reversal 11.8
48 conjunctival squamous cell carcinoma 11.8
49 vulva squamous cell carcinoma 11.8
50 basaloid squamous cell carcinoma 11.8

Graphical network of the top 20 diseases related to Squamous Cell Carcinoma:



Diseases related to Squamous Cell Carcinoma

Symptoms & Phenotypes for Squamous Cell Carcinoma

Drugs & Therapeutics for Squamous Cell Carcinoma

Drugs for Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 545)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Petrolatum Approved, Investigational Phase 4 8009-03-8
2
Mometasone furoate Approved, Investigational, Vet_approved Phase 4 83919-23-7 4240 441336
3
Titanium dioxide Approved Phase 4 13463-67-7
4
Cevimeline Approved Phase 4 107233-08-9 83898 25137844 2684
5
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
6
Raltitrexed Approved, Investigational Phase 4 112887-68-0 104758 135400182
7
Diclofenac Approved, Vet_approved Phase 4 15307-86-5, 15307-79-6 3033
8
Tirbanibulin Approved, Investigational Phase 4 897016-82-9 23635314
9
Cetuximab Approved Phase 4 205923-56-4
10
Mitomycin Approved Phase 4 50-07-7 5746
11 Endostar protein Phase 4
12 Endostatins Phase 4
13 Anti-Allergic Agents Phase 4
14 Cholinergic Agents Phase 4
15 Muscarinic Agonists Phase 4
16 Fibrin Tissue Adhesive Phase 4
17 Tin Fluorides Phase 4
18
Triamcinolone hexacetonide Phase 4
19
Triamcinolone diacetate Phase 4
20
Triamcinolone Acetonide Phase 4 6436
21 Anti-Bacterial Agents Phase 4
22 Antibiotics, Antitubercular Phase 4
23 Alkylating Agents Phase 4
24
Trioxsalen Approved Phase 3 3902-71-4 5585
25
Fluorouracil Approved Phase 3 51-21-8 3385
26
Hydroxyurea Approved Phase 2, Phase 3 127-07-1 3657
27
Crizotinib Approved, Investigational Phase 3 877399-52-5 11626560
28
Amifostine Approved, Investigational Phase 3 20537-88-6 2141
29
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
30
Cobalt Approved, Experimental, Withdrawn Phase 3 7440-48-4 104729
31
Doxycycline Approved, Investigational, Vet_approved Phase 3 564-25-0 54671203
32
Tocopherol Approved, Investigational Phase 3 1406-66-2
33
Dapsone Approved, Investigational Phase 3 80-08-0 2955
34
Minocycline Approved, Investigational Phase 3 10118-90-8, 13614-98-7 54675783 5281021
35
Levoleucovorin Approved, Experimental, Investigational Phase 3 68538-85-2, 58-05-9, 73951-54-9 149436 6006
36
Sodium citrate Approved, Investigational Phase 2, Phase 3 68-04-2 23431961
37
Gemcitabine Approved Phase 3 95058-81-4, 122111-03-9 60750
38
Calcipotriol Approved Phase 2, Phase 3 112965-21-6 5288783
39
Pembrolizumab Approved Phase 3 1374853-91-4 254741536
40
Cemiplimab Approved, Investigational Phase 3 1801342-60-8
41
Ipilimumab Approved Phase 3 477202-00-9
42
Pemetrexed Approved, Investigational Phase 3 150399-23-8, 137281-23-3 60843 446556 135565230
43
Olaparib Approved Phase 3 763113-22-0 23725625
44
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 4112 126941
45
Vinorelbine Approved, Investigational Phase 3 71486-22-1 44424639 60780
46
Imiquimod Approved, Investigational Phase 3 99011-02-6 57469
47
Topotecan Approved, Investigational Phase 3 123948-87-8, 119413-54-6 60699 60700
48
Carboplatin Approved Phase 3 41575-94-4 10339178 38904
49
Erlotinib Approved, Investigational Phase 2, Phase 3 183319-69-9, 183321-74-6 176870
50
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124

Interventional clinical trials:

(show top 50) (show all 2570)
# Name Status NCT ID Phase Drugs
1 Apatinib Mesylate Was Used in the Treament of Patients With Advanced Lung Squamous Cell Carcinoma of the Third Line and Above Unknown status NCT03725423 Phase 4 Apatinib
2 An Open-label, Single-arm Clinical Study to Evaluate the Efficacy of Afatinib in Advanced Lung Squamous Cell Carcinoma With EGFR Sensitive Mutation Unknown status NCT04132102 Phase 4 Afatinib
3 A Prospective Randomized Controlled Clinical Study of Albumin-bound Paclitaxel Combined With Cisplatin (AP Regimen) Versus Docetaxel Combined With Cisplatin (TP Regimen) Induced Chemotherapy in Advanced Head and Neck Squamous Tummor Unknown status NCT04766827 Phase 4 albumin-bound paclitaxel
4 Mometasone Furoate Cream Reduces Acute Radiation Dermatitis in Head and Neck Squamous Cell Carcinomas' Patients Receiving Radiation Therapy Unknown status NCT02495064 Phase 4 Mometasone Furoate Cream
5 A Double-Blind, Placebo-Controlled, Randomized Clinical Trial of Sodium Glycididazole in Concurrent Radiochemotherapy for the Treatment of Thoracic Esophageal Squamous Carcinoma Unknown status NCT00642239 Phase 4 placebo;Sodium Glycididazole
6 Endostar First-line Treatment of Advanced Non-small Cell Lung Squamous Carcinoma Based on Chemotherapy for Advanced Non-small Cell Lung Squamous Carcinoma Patients:a Randomized Controlled,Open, Multicenter Clinical Study Unknown status NCT02513342 Phase 4 Docetaxel;Cisplatin
7 A Clinical Trial of ALA Photodynamic Therapy for Treatment of Actinic Cheilitis in Patients With Squamous Cell Carcinoma of the Lip. Completed NCT00868088 Phase 4
8 Phase IV Clinical Study Evaluating The Efficacy of Chemoradiotherapy Following Neoadjuvant Treatment With Docetaxel and Cisplatin in Indifferentiated and Non-keratinized Squamous Cell Carcinoma of Nasopharynx Completed NCT00772681 Phase 4 docetaxel and cisplatin
9 Nedaplatin (Jiebaishu®) and Docetaxel in Comparison With Cisplatin and Docetaxel Regimen for the First Line Treatment of Advanced Squamous Cell Carcinoma of Lung(IIIB/IV): Randomized, Controlled, Multicentre Study Completed NCT02088515 Phase 4 Nedaplatin;Cisplatin;Docetaxel
10 An Investigator-Initiated,Multicenter,Randomized,Double-Blind Placebo-Controlled Design Study to Assess the Effectiveness of CeviMeline to Improve OraL Health in Patients With XErostomia Secondary to Radiation Therapy for Treatment of Head and Neck Squamous Cell Carcinoma Completed NCT00466388 Phase 4 Cevimeline
11 Long-term Effects of Aldara® 5% Cream and Solaraze® 3% Gel in the Treatment of Actinic Keratoses on the Face or Scalp With Respect to the Risk of Progression to In-situ and Invasive Squamous Cell Carcinoma Completed NCT01453179 Phase 4 Imiquimod;Diclofenac
12 Comparison Between Two Regimens of Chemotherapy Concurrent With Radiotherapy in Locally Advanced Head and Neck Cancer Completed NCT03998696 Phase 4 Cisplatin 40 mg/m2;Cisplatin 100 mg/m2
13 Phase IV Trial to Use Stereotactic Body Radiotherapy for Head and Neck Tumors Completed NCT01344356 Phase 4
14 Safety and Efficacy of Nab-paclitaxel (Abraxane) in Combination With Carboplatin as First Line Treatment in Elderly Subjects With Advance Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, Multicenter Study (Abound.70+) Completed NCT02151149 Phase 4 nab-paclitaxel;Carboplatin
15 CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial Completed NCT00847912 Phase 4 5-fluorouracil;Placebo, vehicle control
16 Can Fibrin Sealant be Used to Reduce Post-operative Drainage Following Lymph Node Dissection: a Prospective Randomised Double Blind Trial. Completed NCT00324272 Phase 4 Fibrin Sealant (Tisseel) used in the Experimental Arm.
17 Radiotherapy Combine With Raltitrexed Versus Radiotherapy Alone in Older Patients With Head and Neck Squamous Cell Carcinoma: a Prospective Randomized Controlled Trial Recruiting NCT03196843 Phase 4 Raltitrexed
18 A Phase 4, Multi-centre, Randomized, Evaluator-blinded, Active-controlled Study to Determine the Incidence of Squamous Cell Carcinoma and Evaluate the Long-term Safety of Tirbanibulin 10 mg/g Ointment and Diclofenac Sodium 3% Gel for the Treatment of Adult Patients With Actinic Keratosis on the Face or Scalp Recruiting NCT05387525 Phase 4 Tirbanibulin (Klisyri®) 10 mg/g ointment;Diclofenac Sodium 3% Gel
19 Sun Yat-sen Memorial Hospital, Sun Yat-sen University Recruiting NCT05444673 Phase 4 Paprizumab combined with cisplatin and 5-FU
20 A Phase 4, Single-arm, Open-label Clinical Study of Pembrolizumab (MK-3475) to Evaluate the Efficacy and Safety of MK-3475 Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE B10). Active, not recruiting NCT04489888 Phase 4 Pembrolizumab;Carboplatin;Paclitaxel
21 Randomized Phase IV Trial to Compare Cetuximab With Concomitant Radiation Therapy With Concomitant Mitomycin-C and 5-Fluorouracil With Radiation Therapy for Locally Advanced Squamous Cell Carcinomas of the Head and Neck Terminated NCT02015650 Phase 4 Cetuximab;Mitomycin-C/ 5-Fluorouracil
22 Radiotherapy Dose Escalation in Locally Advanced Squamous Cell Carcinoma of the Larynx or Hypopharynx Withdrawn NCT03388931 Phase 4
23 Acitretin Plasma Levels Under Hemodialysis Withdrawn NCT00488384 Phase 4 Chemopreventive application (Acitretin)
24 Two-arm Phase III Trial Comparing Different Time of Endoscopic Photodynamic Therapy on Esophageal and/or Gastric Cardiac Cancer Unknown status NCT02628665 Phase 3 photosensitizer(photofrin)
25 Three-arm Phase III Trial Comparing Radiotherapy With Different Chemotherapy Regimens for Esophageal Cancer Unknown status NCT02025036 Phase 3 Capecitabine(Aibin);Oxaliplatin(Aiheng)
26 Two-arm Phase III Trial Comparing Radiotherapy With Differentcycles of Cisplatin-5-fluorouracil for Esophageal Cancer Unknown status NCT02607540 Phase 3
27 Different Cycles of Capecitabine Usage in Esophageal Cancer Concurrent Chemoradiotherapy Unknown status NCT02603159 Phase 3 Capecitabine(Aibin)
28 Evaluation of the Benefits of Oral Metronomic Cyclophosphamide in Combination With Standard Cisplatin-etoposide Based Chemotherapy for Squamous Cell Lung Carcinoma Unknown status NCT01947062 Phase 3 Intravenous Cisplatin & etoposide;Intravenous Cisplatin & etoposide along with oral cyclophosphamide
29 SCT-I10A Combined With Standard Chemotherapy Versus Placebo Combined With Standard Chemotherapy in First-line Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC): A Phase III, Multicenter, Randomized, Double-blinded Trial Unknown status NCT04146402 Phase 3 SCT-I10A+chemo;Placebos+chemo
30 A Multicenter, Randomized, Open-label, Phase III Trail of Adjuvant Chemoradiotherapy Versus Adjuvant Radiotherapy in Patients Undergoing Radical Esophagectomy for Pathologic Lymph Node Positive Esophageal Squamous Cell Carcinoma Unknown status NCT02570893 Phase 3 Paclitaxel and carboplatin
31 Determination of Epidermal Growth Factor Receptor-inhibitor (Cetuximab) Versus Standard Chemotherapy (Cisplatin) Early And Late Toxicity Events in Human Papillomavirus-positive Oropharyngeal Squamous Cell Carcinoma Unknown status NCT01874171 Phase 3 Cisplatin;Cetuximab
32 Multicenter, Randomized, Double-blind, Phase Ⅲ Clinical Study to Evaluate the Efficacy and Safety of TQB2450 Plus Chemotherapy(Cisplatin or Carboplatin+ 5-Fluorouracil (5-FU) ) Versus Placebo Plus Chemotherapy as First-Line Treatment in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma(R/M SCCHN) Unknown status NCT03855384 Phase 3 TQB2450+cisplatin or carboplatin + 5-Fluorouracil (5-FU);placebo+cisplatin or carboplatin + 5-Fluorouracil (5-FU)
33 An Open, Multicenter, Randomized Phase III Clinical Study on Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma Unknown status NCT02677597 Phase 3 Cisplatin Combined With S-1;Cisplatin Combined With Paclitaxel
34 A Randomized, Open-label, Multi-center Phase III Study Designed to Evaluate the Safety and Efficacy of E10A in Patients With Recurrent/Unresectable Squamous Cell Carcinoma of the Head and Neck Region Unknown status NCT02630264 Phase 3 Endostatins;Paclitaxel injection;Cisplatin injection
35 RANDOMIZED TRIAL OF NEOADJUVANT CHEMOTHERAPY AND SURGERY +/- RADIOTHERAPY VERSUS SURGEERY +/- RADIOTHERAPY IN OPERABLE SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY Unknown status NCT00002747 Phase 3 cisplatin;fluorouracil
36 Randomised Clinical Phase III Study of Radiotherapy Dose, Volume Evaluation for 3DCRT Versus IGRT and Analysis of Early Response in Head and Neck Squamous Cell Carcinoma Unknown status NCT01124409 Phase 3
37 Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Squamous Cell Carcinoma (ESWN 01 Trial): a Phase 3, Prospective,Multicenter, Randomised Study Unknown status NCT02319187 Phase 3 S1;S-1;irinotecan
38 Observational Clinical Trial of Adjuvant Chemotherapy for Non-squamous Cell Carcinoma of Non-small Cell Lung Cancer Unknown status NCT03656393 Phase 3 Gefitinib;Vinorelbine;Carboplatin
39 Controlled Randomized Trial to Evaluate Efficacy of Adjuvant Chemotherapy Between S-1 and UFT for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Phase III Study Unknown status NCT00336947 Phase 3 tegafur-gimeracil-oteracil potassium;tegafur-uracil
40 A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFECT OF CISPLATIN/EPINEPHRINE INJECTABLE GEL (PRODUCT MPI 5010) WHEN ADMINISTERED INTRATUMORALLY FOR ACHIEVEMENT OF TREATMENT GOALS IN RECURRENT OR REFRACTORY SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK Unknown status NCT00002659 Phase 3 cisplatin-e therapeutic implant
41 A Randomized, Controlled, Double-blind Study to Evaluate Efficacy and Survival of Combining Nimotuzumab Plus Concurrent Chemo-radiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma Unknown status NCT02409186 Phase 3 Nimotuzumab;chemoradiotherapy Paclitaxel;chemoradiotherapy Cisplatin
42 Multicentre Randomised Trial of Inductive and Adjuvant Perilymphatically Injected Proleukin (rlL-2) in The Treatment of Operable Primary Squamous Cell Carcinoma of The Oral Cavity and Oropharynx Unknown status NCT00002702 Phase 3
43 The Randomized,Open, Multicenter Phase III Study to Compare the Effectiveness and Safety of Nab-Paclitaxel Versus Paclitaxel Plus Carboplatin First-Line Therapy Advanced Non Small Cell Lung Cancer Squamous Cell Carcinoma Unknown status NCT03262948 Phase 3 nab-paclitaxel;Paclitaxel;Carboplatin
44 A Randomized Phase II Trial Evaluating The Addition Of Nimotuzumab To Chemoradiation For Patients With Esophageal Squamous Cell Carcinoma After Radical Esophagectomy Who Suffer With Lymph Nodes Recurrence Unknown status NCT01402180 Phase 2, Phase 3 chemotherapy
45 Multi-center Prospective Randomized Controlled Clinical Trial of Postoperative Adjuvant Chemotherapy, Adjuvant Radiotherapy, or Surgery Alone for High-risk Histological Node Negative Patients With Thoracic Esophageal Squamous Cell Carcinoma Unknown status NCT02891083 Phase 3 Adjuvant chemotherapy (Paclitaxel and Cisplatin)
46 Phase Ⅲ Study of Prophylactic Postoperative Intensity Modulated Radiation Therapy in Stage T2-3N0M0 Disease of Thoracic Esophageal Squamous Cell Carcinoma; Unknown status NCT01745107 Phase 3
47 Is Elective Nodal Irradiation (ENI) Necessary For Patients With Thoracic Esophageal Squamous Cell Carcinoma Who Undergo Esophagectomy And With Pathological Stage Of T1-2,N+,M0 -- A Randomized Phase Ⅲ Trial Unknown status NCT01398449 Phase 3
48 Chemoprevention of Esophageal Squamous Cell Carcinoma With Aspirin and Tea Polyphenols: a Randomized Controlled Trial. Unknown status NCT01496521 Phase 3 Aspirin
49 Postoperative Radiation and Concurrent Chemotherapy With Weekly Docetaxel Versus Cisplatin in Patients With High Risk Squamous Cell Carcinoma of Head & Neck: a Randomized Multi-center Phase III Clinical Trial Unknown status NCT02923258 Phase 2, Phase 3 Docetaxel;Cisplatinum
50 International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study) Unknown status NCT02305654 Phase 3 Paclitaxel;Ifosfamide;Cisplatin

Search NIH Clinical Center for Squamous Cell Carcinoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Afatinib
afatinib dimaleate
pembrolizumab

Cochrane evidence based reviews: carcinoma, squamous cell

Genetic Tests for Squamous Cell Carcinoma

Genetic tests related to Squamous Cell Carcinoma:

# Genetic test Affiliating Genes
1 Squamous Cell Carcinoma 28

Anatomical Context for Squamous Cell Carcinoma

Organs/tissues related to Squamous Cell Carcinoma:

MalaCards : Skin, Lymph Node, Tongue, Lung, Cervix, T Cells, Myeloid

Publications for Squamous Cell Carcinoma

Articles related to Squamous Cell Carcinoma:

(show top 50) (show all 47763)
# Title Authors PMID Year
1
Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 5
25157968 2014
2
Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia. 5
23932362 2013
3
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. 5
22328973 2011
4
Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. 5
18938156 2008
5
Expression of CC-chemokine receptor 7 (CCR7) and CXC-chemokine receptor 4 (CXCR4) in head and neck squamous cell carcinoma. 53 62
20036791 2010
6
Antitumor effects of inhibitors of nitric oxide synthase or cyclooxygenase-2 on human KB carcinoma cells overexpressing COX-2. 53 62
20514441 2010
7
Carrier cell-mediated cell lysis of squamous cell carcinoma cells by squamous cell carcinoma antigen 1 promoter-driven oncolytic adenovirus. 53 62
20527047 2010
8
Tumor-related protein, the squamous cell carcinoma antigen binds to the intracellular protein carbonyl reductase. 53 62
20428762 2010
9
EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma. 53 62
20415599 2010
10
Phase II prospective trial of gefitinib given concurrently with cisplatin and radiotherapy in patients with locally advanced head and neck cancer. 53 62
20470671 2010
11
Expression and mutation analysis of her2 in head and neck squamous cell carcinoma. 53 62
20014947 2010
12
Mammalian target of rapamycin (mTOR) is involved in the survival of cells mediated by chemokine receptor 7 through PI3K/Akt in metastatic squamous cell carcinoma of the head and neck. 53 62
19615795 2010
13
EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation. 53 62
20360610 2010
14
Downregulation of N-cadherin expression inhibits invasiveness, arrests cell cycle and induces cell apoptosis in esophageal squamous cell carcinoma. 53 62
20014942 2010
15
Nerve growth factor and tyrosine kinase A receptor in oral squamous cell carcinoma: is there an association with perineural invasion? 53 62
20363547 2010
16
Loss expression of O6-methylguanine DNA methyltransferase by promoter hypermethylation and its relationship to betel quid chewing in oral squamous cell carcinoma. 53 62
20451846 2010
17
Naphtho[1,2-b]furan-4,5-dione induces apoptosis of oral squamous cell carcinoma: involvement of EGF receptor/PI3K/Akt signaling pathway. 53 62
20371243 2010
18
Reactive oxygen species produced by the knockdown of manganese-superoxide dismutase up-regulate hypoxia-inducible factor-1alpha expression in oral squamous cell carcinoma cells. 53 62
20188165 2010
19
Potential role of HDAC inhibitors in cancer therapy: insights into oral squamous cell carcinoma. 53 62
20207580 2010
20
Impact of podoplanin expression in oral squamous cell carcinoma: clinical and histopathologic correlations. 53 62
20393745 2010
21
Decreased GRP78 protein expression is a potential prognostic marker of oral squamous cell carcinoma in Taiwan. 53 62
20497865 2010
22
The role of thymidine phosphorylase in the induction of early growth response protein-1 and thrombospondin-1 by 5-fluorouracil in human cancer carcinoma cells. 53 62
20372793 2010
23
Metastases of squamous cell carcinoma of the head and neck show increased levels of nucleotide excision repair protein XPF in vivo that correlate with increased chemoresistance ex vivo. 53 62
20372803 2010
24
TGFbeta1 genetic polymorphism is associated with survival in head and neck squamous cell carcinoma independent of the severity of chemoradiotherapy induced mucositis. 53 62
20308003 2010
25
Regulation of p63 isoforms by snail and slug transcription factors in human squamous cell carcinoma. 53 62
20150431 2010
26
E-cadherin differentially regulates the assembly of Connexin43 and Connexin32 into gap junctions in human squamous carcinoma cells. 53 62
20086013 2010
27
Inhibitory effect of curcumin on motility of human oral squamous carcinoma YD-10B cells via suppression of ERK and NF-kappaB activations. 53 62
19777504 2010
28
Aspirin induces apoptosis in YD-8 human oral squamous carcinoma cells through activation of caspases, down-regulation of Mcl-1, and inactivation of ERK-1/2 and AKT. 53 62
20116423 2010
29
Plakoglobin interacts with and increases the protein levels of metastasis suppressor Nm23-H2 and regulates the expression of Nm23-H1. 53 62
20101217 2010
30
Interaction of syndecan and alpha6beta4 integrin cytoplasmic domains: regulation of ErbB2-mediated integrin activation. 53 62
20181947 2010
31
HLA class I antigen and transporter associated with antigen processing downregulation in metastatic lesions of head and neck squamous cell carcinoma as a marker of poor prognosis. 53 62
20204276 2010
32
Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma. 53 62
20215534 2010
33
Antitumor effects of lapatinib (GW572016), a dual inhibitor of EGFR and HER-2, in combination with cisplatin or paclitaxel on head and neck squamous cell carcinoma. 53 62
20204279 2010
34
TrkB induces EMT and has a key role in invasion of head and neck squamous cell carcinoma. 53 62
20101235 2010
35
[Expression of alpha-tubulin and MDR1 and their correlation with the biological features of non-small cell lung carcinoma]. 53 62
20510079 2010
36
Expression of nucleostemin, epidermal growth factor and epidermal growth factor receptor in human esophageal squamous cell carcinoma tissues. 53 62
19823871 2010
37
[Clinicopathological significance of expressions of RECK and MMP-2 in esophageal squamous carcinoma]. 53 62
20510080 2010
38
The predictive value of genes of the TGF-beta1 pathway in multimodally treated squamous cell carcinoma of the esophagus. 53 62
20012971 2010
39
Prediction of CCND1 amplification using plasma DNA as a prognostic marker in oesophageal squamous cell carcinoma. 53 62
20389301 2010
40
mTOR inhibitor rapamycin alone or combined with cisplatin inhibits growth of esophageal squamous cell carcinoma in nude mice. 53 62
19853373 2010
41
Vimentin expression of esophageal squamous cell carcinoma and its aggressive potential for lymph node metastasis. 53 62
20460738 2010
42
p16INK4a hypermethylation and p53, p16 and MDM2 protein expression in esophageal squamous cell carcinoma. 53 62
20388212 2010
43
VEGF-C contributes to head and neck squamous cell carcinoma growth and motility. 53 62
20227330 2010
44
GLUT1 and GLUT3 as potential prognostic markers for Oral Squamous Cell Carcinoma. 53 62
20428049 2010
45
Fatty-acid-binding protein 5 promotes cell proliferation and invasion in oral squamous cell carcinoma. 53 62
20040021 2010
46
Co-expression of Hif1alpha and CAIX is associated with poor prognosis in oral squamous cell carcinoma patients. 53 62
19780905 2010
47
Two members of the SIBLING family of proteins, DSPP and BSP, may predict the transition of oral epithelial dysplasia to oral squamous cell carcinoma. 53 62
20186700 2010
48
Minichromosome maintenance-7 and geminin are reliable prognostic markers in patients with oral squamous cell carcinoma: immunohistochemical study. 53 62
20136698 2010
49
Clinical significance of EGFR, Her-2 and EGF in oral squamous cell carcinoma: a case control study. 53 62
20429940 2010
50
Cobalt chloride stimulates phosphoinositide 3-kinase/Akt signaling through the epidermal growth factor receptor in oral squamous cell carcinoma. 53 62
20506627 2010

Variations for Squamous Cell Carcinoma

ClinVar genetic disease variations for Squamous Cell Carcinoma:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 DDR2 NM_006182.4(DDR2):c.2304T>A (p.Ser768Arg) SNV Pathogenic
375878 rs267598140 GRCh37: 1:162748390-162748390
GRCh38: 1:162778600-162778600
2 EGFR-AS1, EGFR NM_005228.5(EGFR):c.2428G>A (p.Gly810Ser) SNV Likely Pathogenic
376278 rs121913230 GRCh37: 7:55249130-55249130
GRCh38: 7:55181437-55181437
3 EGFR-AS1, EGFR NM_005228.5(EGFR):c.2429G>A (p.Gly810Asp) SNV Likely Pathogenic
376279 rs121913431 GRCh37: 7:55249131-55249131
GRCh38: 7:55181438-55181438

Cosmic variations for Squamous Cell Carcinoma:

8 (show top 50) (show all 1992)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM112254631 TP53 skin,face,carcinoma,squamous cell carcinoma c.586C>T p.R196* 17:7674945-7674945 18
2 COSM143943797 TP53 skin,neck,carcinoma,squamous cell carcinoma c.266G>A p.R89Q 17:7674220-7674220 18
3 COSM121875437 TP53 skin,face,carcinoma,squamous cell carcinoma c.178C>T p.Q60* 17:7674957-7674957 18
4 COSM143388508 TP53 skin,face,carcinoma,squamous cell carcinoma c.629G>C p.R210T 17:7674217-7674217 18
5 COSM111758868 TP53 skin,face,carcinoma,squamous cell carcinoma c.742C>T p.R248W 17:7674221-7674221 18
6 COSM142560384 TP53 skin,face,carcinoma,squamous cell carcinoma c.616G>T p.G206C 17:7674230-7674230 18
7 COSM144021997 TP53 skin,face,carcinoma,squamous cell carcinoma c.421C>T p.P141S 17:7675158-7675158 18
8 COSM144658487 TP53 skin,face,carcinoma,squamous cell carcinoma c.143C>A p.P48Q 17:7676109-7676109 18
9 COSM142639459 TP53 skin,face,carcinoma,squamous cell carcinoma c.597T>A p.C199* 17:7674249-7674249 18
10 COSM105620390 TP53 skin,face,carcinoma,squamous cell carcinoma c.733G>T p.G245C 17:7674230-7674230 18
11 COSM112263720 TP53 skin,face,carcinoma,squamous cell carcinoma c.832C>T p.P278S 17:7673788-7673788 18
12 COSM93239210 TP53 skin,face,carcinoma,squamous cell carcinoma c.706T>C p.Y236H 17:7674257-7674257 18
13 COSM105620642 TP53 skin,face,carcinoma,squamous cell carcinoma c.742C>T p.R248W 17:7674221-7674221 18
14 COSM143949062 TP53 skin,face,carcinoma,squamous cell carcinoma c.263A>C p.N88T 17:7674223-7674223 18
15 COSM111775215 TP53 skin,face,carcinoma,squamous cell carcinoma c.746G>C p.R249T 17:7674217-7674217 18
16 COSM144129318 TP53 skin,face,carcinoma,squamous cell carcinoma c.229T>C p.Y77H 17:7674257-7674257 18
17 COSM144088618 TP53 skin,face,carcinoma,squamous cell carcinoma c.160C>T p.R54* 17:7674894-7674894 18
18 COSM87910628 TP53 skin,face,carcinoma,squamous cell carcinoma c.772G>A p.E258K 17:7674191-7674191 18
19 COSM144662686 TP53 skin,face,carcinoma,squamous cell carcinoma c.715C>T p.P239S 17:7673788-7673788 18
20 COSM144650676 TP53 skin,face,carcinoma,squamous cell carcinoma c.457C>T p.Q153* 17:7674957-7674957 18
21 COSM142560553 TP53 skin,face,carcinoma,squamous cell carcinoma c.625C>T p.R209W 17:7674221-7674221 18
22 COSM93194159 TP53 skin,face,carcinoma,squamous cell carcinoma c.832C>T p.P278S 17:7673788-7673788 18
23 COSM142560281 TP53 skin,neck,carcinoma,squamous cell carcinoma c.626G>A p.R209Q 17:7674220-7674220 18
24 COSM93183975 TP53 skin,face,carcinoma,squamous cell carcinoma c.742C>T p.R248W 17:7674221-7674221 18
25 COSM93199912 TP53 skin,face,carcinoma,squamous cell carcinoma c.746G>C p.R249T 17:7674217-7674217 18
26 COSM144023384 TP53 skin,face,carcinoma,squamous cell carcinoma c.739G>A p.E247K 17:7674191-7674191 18
27 COSM145020185 TP53 skin,face,carcinoma,squamous cell carcinoma c.520C>T p.R174* 17:7674894-7674894 18
28 COSM105630961 TP53 skin,face,carcinoma,squamous cell carcinoma c.782+393C>T p.? 17:7673788-7673788 18
29 COSM111758130 TP53 skin,face,carcinoma,squamous cell carcinoma c.574C>T p.Q192* 17:7674957-7674957 18
30 COSM122749884 TP53 skin,face,carcinoma,squamous cell carcinoma c.350G>C p.R117T 17:7674217-7674217 18
31 COSM106052835 TP53 skin,face,carcinoma,squamous cell carcinoma c.574C>T p.Q192* 17:7674957-7674957 18
32 COSM144023287 TP53 skin,face,carcinoma,squamous cell carcinoma c.799C>T p.P267S 17:7673788-7673788 18
33 COSM142838067 TP53 skin,face,carcinoma,squamous cell carcinoma c.586C>T p.R196* 17:7674945-7674945 18
34 COSM143946062 TP53 skin,face,carcinoma,squamous cell carcinoma c.160C>T p.R54* 17:7674894-7674894 18
35 COSM121887849 TP53 skin,face,carcinoma,squamous cell carcinoma c.436C>T p.P146S 17:7673788-7673788 18
36 COSM144652672 TP53 skin,face,carcinoma,squamous cell carcinoma c.739G>A p.E247K 17:7673764-7673764 18
37 COSM142843719 TP53 skin,face,carcinoma,squamous cell carcinoma c.454C>T p.P152S 17:7675158-7675158 18
38 COSM87910495 TP53 skin,face,carcinoma,squamous cell carcinoma c.832C>T p.P278S 17:7673788-7673788 18
39 COSM105619751 TP53 skin,face,carcinoma,squamous cell carcinoma c.574C>T p.Q192* 17:7674957-7674957 18
40 COSM144318661 TP53 skin,face,carcinoma,squamous cell carcinoma c.655G>A p.E219K 17:7674191-7674191 18
41 COSM144091278 TP53 skin,face,carcinoma,squamous cell carcinoma c.263A>C p.N88T 17:7674223-7674223 18
42 COSM144652296 TP53 skin,face,carcinoma,squamous cell carcinoma c.469C>T p.R157* 17:7674945-7674945 18
43 COSM144311933 TP53 skin,face,carcinoma,squamous cell carcinoma c.520C>T p.R174* 17:7674894-7674894 18
44 COSM111812818 TP53 skin,face,carcinoma,squamous cell carcinoma c.706T>C p.Y236H 17:7674257-7674257 18
45 COSM105627464 TP53 skin,face,carcinoma,squamous cell carcinoma c.260C>A p.P87Q 17:7676109-7676109 18
46 COSM144013676 TP53 skin,face,carcinoma,squamous cell carcinoma c.709C>T p.R237W 17:7674221-7674221 18
47 COSM122734399 TP53 skin,face,carcinoma,squamous cell carcinoma c.346C>T p.R116W 17:7674221-7674221 18
48 COSM142837995 TP53 skin,face,carcinoma,squamous cell carcinoma c.375+1G>A p.? 17:7675993-7675993 18
49 COSM106055208 TP53 skin,face,carcinoma,squamous cell carcinoma c.637C>T p.R213* 17:7674894-7674894 18
50 COSM142881780 TP53 skin,face,carcinoma,squamous cell carcinoma c.706T>C p.Y236H 17:7674257-7674257 18

Copy number variations for Squamous Cell Carcinoma from CNVD:

6 (show top 50) (show all 98)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13821 1 1 7200000 Copy number TP73 Squamous cell cancer
2 25151 1 184907591 184916179 Amplification PTGS2 Squamous cell cancer
3 31938 1 32200000 39600000 Copy number Squamous cell cancer
4 33706 1 47467454 47552406 Amplification STIL Squamous cell cancer
5 42802 10 40300000 135374737 Copy number Squamous cell cancer
6 49690 11 110000000 134452384 Copy number Squamous cell cancer
7 49993 11 112500000 114500000 Copy number CADM1 Squamous cell cancer
8 57469 11 63400000 77100000 Copy number GSTP1 Squamous cell cancer
9 57471 11 63400000 77100000 Copy number MEN1 Squamous cell cancer
10 61508 12 1 3100000 Gain Squamous cell cancer
11 61509 12 1 3100000 Gain SLC6A12 Squamous cell cancer
12 61511 12 1 3100000 Gain SLC6A13 Squamous cell cancer
13 61529 12 1 35400000 Copy number Squamous cell cancer
14 61608 12 10000000 12600000 Gain CDKN1B Squamous cell cancer
15 61609 12 10000000 12600000 Gain APOLD1 Squamous cell cancer
16 66096 12 25249446 25295130 Amplification KRAS Squamous cell cancer
17 66577 12 3100000 5300000 Gain Squamous cell cancer
18 66579 12 3100000 5300000 Gain Squamous cell cancer
19 66581 12 3100000 5300000 Gain TSPAN9 Squamous cell cancer
20 75264 13 18400000 72100000 Copy number Squamous cell cancer
21 77032 13 39500000 46200000 Copy number Squamous cell cancer
22 87575 14 74815283 74818665 Amplification FOS Squamous cell cancer
23 93656 15 57100000 61500000 Loss RORA Squamous cell cancer
24 95697 15 79500000 83000000 Loss DNM1P41 Squamous cell cancer
25 95699 15 79500000 83000000 Loss Squamous cell cancer
26 95701 15 79500000 83000000 Loss Squamous cell cancer
27 95703 15 79500000 83000000 Loss Squamous cell cancer
28 95705 15 79500000 83000000 Loss Squamous cell cancer
29 95707 15 79500000 83000000 Loss LOC440300 Squamous cell cancer
30 95709 15 79500000 83000000 Loss Squamous cell cancer
31 97922 16 14700000 16700000 Loss Squamous cell cancer
32 107539 17 15900000 22100000 Loss Squamous cell cancer
33 111141 17 35097918 35138441 Amplification ERBB2 Squamous cell cancer
34 116535 17 6800000 11200000 Copy number Squamous cell cancer
35 122734 18 59800000 76117153 Copy number Squamous cell cancer
36 123838 18 89115825 89123587 Amplification SPP1 Squamous cell cancer
37 124166 19 1 6900000 Gain BSG Squamous cell cancer
38 124167 19 1 6900000 Gain ODF3L2 Squamous cell cancer
39 124168 19 1 6900000 Gain TPGS1 Squamous cell cancer
40 124170 19 1 6900000 Gain CDC34 Squamous cell cancer
41 124171 19 1 6900000 Gain GZMM Squamous cell cancer
42 124173 19 1 6900000 Gain MADCAM1 Squamous cell cancer
43 124175 19 1 6900000 Gain Squamous cell cancer
44 135627 2 118600000 122100000 Gain Squamous cell cancer
45 166091 3 1 3500000 Loss APOD Squamous cell cancer
46 166092 3 1 3500000 Loss CCR2 Squamous cell cancer
47 166093 3 1 3500000 Loss CCRL2 Squamous cell cancer
48 169828 3 14700000 30800000 Copy number Squamous cell cancer
49 171547 3 169200000 172500000 Gain MECOM Squamous cell cancer
50 171549 3 169200000 172500000 Gain Squamous cell cancer

Expression for Squamous Cell Carcinoma

Search GEO for disease gene expression data for Squamous Cell Carcinoma.

Pathways for Squamous Cell Carcinoma

GO Terms for Squamous Cell Carcinoma

Sources for Squamous Cell Carcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....